At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EIKN Eikon Therapeutics
Trading 09-14 10:56:49 EDT
9.08
+0.14
+1.57%
High9.18Low8.93Vol98.92K
Open8.95D1 Closing8.94Amplitude2.77%
Mkt Cap490.18MTradable Cap160.24MTotal Shares53.98M
T/O896.66KT/O Rate0.56%Tradable Shares17.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Major Investor Makes Bold Move on Eikon Therapeutics Shares
TIPRANKS  ·  09-09
Major Investor Makes Bold Move on Eikon Therapeutics Shares
Column Group IV GP Reports Purchase of 89,200 Eikon Therapeutics Shares Valued at $1.03 Million
Reuters  ·  09-09
Column Group IV GP Reports Purchase of 89,200 Eikon Therapeutics Shares Valued at $1.03 Million
Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer
Reuters  ·  09-03
Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer
Eikon Therapeutics Appoints Ching-Pin Chang, M.d., Ph.d. as Executive Vice President and Chief Scientific Officer
THOMSON REUTERS  ·  09-03
Eikon Therapeutics Appoints Ching-Pin Chang, M.d., Ph.d. as Executive Vice President and Chief Scientific Officer
Press Release: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Dow Jones  ·  09-03
Press Release: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Eikon Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat
Reuters  ·  08-26
Eikon Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat
Eikon Therapeutics to Participate in Investor Conferences in September 2026
GlobeNewswire  ·  08-26
Eikon Therapeutics to Participate in Investor Conferences in September 2026
Eikon CEO Perlmutter Joins Cantor Fitzgerald KOL Webcast on PARP Inhibitors in Oncology
Reuters  ·  08-19
Eikon CEO Perlmutter Joins Cantor Fitzgerald KOL Webcast on PARP Inhibitors in Oncology
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
GlobeNewswire  ·  08-19
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Eikon Therapeutics, Inc. (EIKN) Receives a Buy from Morgan Stanley
TIPRANKS  ·  08-17
Eikon Therapeutics, Inc. (EIKN) Receives a Buy from Morgan Stanley
Eikon Therapeutics Price Target Cut to $4.00/Share from $5.00 by Wedbush
Dow Jones  ·  08-14
Eikon Therapeutics Price Target Cut to $4.00/Share from $5.00 by Wedbush
Eikon Therapeutics Highlights Q3 2026 Oncology Pipeline Progress
TIPRANKS  ·  08-14
Eikon Therapeutics Highlights Q3 2026 Oncology Pipeline Progress
Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate
Benzinga Earnings  ·  08-14
Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate
Eikon Net Loss Narrows 16% to $88.4 Million in Q2 FY26; R&D Expenses Rise 9% to $75.5 Million
Reuters  ·  08-14
Eikon Net Loss Narrows 16% to $88.4 Million in Q2 FY26; R&D Expenses Rise 9% to $75.5 Million
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
GlobeNewswire  ·  08-14
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Eikon Selects 0.6 Mg/m2 Dose for Eik1001 in TeLuRide-006 Advanced Melanoma Trial
Reuters  ·  08-11
Eikon Selects 0.6 Mg/m2 Dose for Eik1001 in TeLuRide-006 Advanced Melanoma Trial
Eikon Therapeutics - DMC Recommends Teluride-006 Study Continue as Planned
THOMSON REUTERS  ·  08-11
Eikon Therapeutics - DMC Recommends Teluride-006 Study Continue as Planned
Eikon Therapeutics Announces Dose Selection for Teluride-006, an Ongoing Adaptive Phase 2/3 Trial of Eik1001 in Advanced Melanoma
THOMSON REUTERS  ·  08-11
Eikon Therapeutics Announces Dose Selection for Teluride-006, an Ongoing Adaptive Phase 2/3 Trial of Eik1001 in Advanced Melanoma
Eikon Therapeutics Appoints Johnny Bennett, Ph.d. to Its Scientific Advisory Board
THOMSON REUTERS  ·  08-10
Eikon Therapeutics Appoints Johnny Bennett, Ph.d. to Its Scientific Advisory Board
Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board
Dow Jones  ·  08-10
Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board

Introduction

Company Name.
Eikon Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Eikon Therapeutics, Inc. was incorporated in Delaware on July 9, 2019. It is a late-stage clinical biopharmaceutical company focused on developing innovative medicines to address significant unmet medical needs, primarily in oncology. The leadership team has a notable track record of successfully developing impactful drugs. The company's strategy leverages a proprietary technology platform to create novel therapies, with lead candidates targeting serious diseases such as advanced melanoma and non-small cell lung cancer.
Issue price:
--